BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35167885)

  • 1. Exploring the Formation Mechanism of Coamorphous Andrographolide-Oxymatrine Based on Molecular Dynamics and Spectroscopy.
    Fang X; Hu Y; Huang Z; Han L; Li B; Lu S; Cao Y
    J Pharm Sci; 2022 Jul; 111(7):2056-2071. PubMed ID: 35167885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coamorphous System of Florfenicol-Oxymatrine for Improving the Solubility and Dissolution Rate of Florfenicol: Preparation, Characterization and Molecular Dynamics Simulation.
    Li B; Hu Y; Guo Y; Xu R; Fang X; Xiao X; Jiang C; Lu S
    J Pharm Sci; 2021 Jun; 110(6):2544-2554. PubMed ID: 33577826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving physicochemical properties and pharmacological activities of ternary co-amorphous systems.
    Fang X; Hu Y; Yang G; Shi W; Lu S; Cao Y
    Eur J Pharm Biopharm; 2022 Dec; 181():22-35. PubMed ID: 36283631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple Strategies to Improve Oral Bioavailability by Fabricating Coamorphous Forms of Ursolic Acid with Piperine: Enhancing Water-Solubility, Permeability, and Inhibiting Cytochrome P450 Isozymes.
    Yu D; Kan Z; Shan F; Zang J; Zhou J
    Mol Pharm; 2020 Dec; 17(12):4443-4462. PubMed ID: 32926628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apigenin-oxymatrine binary co-amorphous mixture: Enhanced solubility, bioavailability, and anti-inflammatory effect.
    Li B; Hu Y; Wu T; Feng Y; Jiang C; Du H; Lu S
    Food Chem; 2022 Mar; 373(Pt B):131485. PubMed ID: 34740050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.
    Heng W; Su M; Cheng H; Shen P; Liang S; Zhang L; Wei Y; Gao Y; Zhang J; Qian S
    Mol Pharm; 2020 Jan; 17(1):84-97. PubMed ID: 31794225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide.
    Su M; Xia Y; Shen Y; Heng W; Wei Y; Zhang L; Gao Y; Zhang J; Qian S
    RSC Adv; 2019 Dec; 10(1):565-583. PubMed ID: 35492562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
    Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
    Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation and Characterization of a Rifampicin Coamorphous Material with Tromethamine Coformer: An Experimental-Theoretical Study.
    Queiroz LHS; Barros RS; de Sousa FF; Lage MR; Sarraguça MC; Ribeiro PRS
    Mol Pharm; 2024 Mar; 21(3):1272-1284. PubMed ID: 38361428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.
    Shayanfar A; Ghavimi H; Hamishekar H; Jouyban A
    J Pharm Pharm Sci; 2013; 16(4):577-87. PubMed ID: 24210065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coamorphous Loratadine-Citric Acid System with Enhanced Physical Stability and Bioavailability.
    Wang J; Chang R; Zhao Y; Zhang J; Zhang T; Fu Q; Chang C; Zeng A
    AAPS PharmSciTech; 2017 Oct; 18(7):2541-2550. PubMed ID: 28224393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coamorphization combined with complexation enhances dissolution of lurasidone hydrochloride and puerarin with synchronized release.
    Wang S; Heng W; Wang X; He X; Zhang Z; Wei Y; Zhang J; Gao Y; Qian S
    Int J Pharm; 2020 Oct; 588():119793. PubMed ID: 32827676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coamorphous repaglinide-saccharin with enhanced dissolution.
    Gao Y; Liao J; Qi X; Zhang J
    Int J Pharm; 2013 Jun; 450(1-2):290-5. PubMed ID: 23612357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the p
    Hu Y; Guo Y; Li B; Xu R; Fang X; Cao Y; Liu Z; Jiang C; Lu S
    ACS Omega; 2021 Feb; 6(4):3106-3119. PubMed ID: 33553927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in coamorphous drug delivery systems.
    Shi Q; Moinuddin SM; Cai T
    Acta Pharm Sin B; 2019 Jan; 9(1):19-35. PubMed ID: 30766775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sinomenine-phenolic acid coamorphous drug systems: Solubilization, sustained release, and improved physical stability.
    Chen X; Li D; Zhang H; Duan Y; Huang Y
    Int J Pharm; 2021 Apr; 598():120389. PubMed ID: 33609724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic insights into the crystallization of coamorphous drug systems.
    Heng W; Song Y; Luo M; Hu E; Wei Y; Gao Y; Pang Z; Zhang J; Qian S
    J Control Release; 2023 Feb; 354():489-502. PubMed ID: 36646287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin.
    Shi X; Song S; Ding Z; Fan B; Huang W; Xu T
    J Pharm Sci; 2019 Sep; 108(9):3020-3028. PubMed ID: 31067482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Physical Stability and Synchronized Release of Febuxostat and Indomethacin in Coamorphous Solids.
    Moinuddin SM; Shi Q; Tao J; Guo M; Zhang J; Xue Q; Ruan S; Cai T
    AAPS PharmSciTech; 2020 Jan; 21(2):41. PubMed ID: 31898765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injection-Molded Coamorphous Tablets: Analysis of Intermolecular Interaction and Crystallization Propensity.
    Tanaka R; Ishihara S; Sasaki T; Hattori Y; Otsuka M
    J Pharm Sci; 2021 Sep; 110(9):3289-3297. PubMed ID: 34147517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.